Original Article

Pediatric Surgery International

, Volume 26, Issue 12, pp 1185-1191

Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells

  • Chen FengAffiliated withDepartment of Pediatrics, Chinese PLA General Hospital
  • , Tianyou WangAffiliated withDepartment of Hematology-Oncology, Capital Institute of Pediatrics
  • , Ruihong TangAffiliated withDepartment of Hematology-Oncology, Capital Institute of Pediatrics
  • , Jianwen WangAffiliated withDepartment of Pediatrics, Chinese PLA General Hospital
  • , Hui LongAffiliated withDepartment of Pediatrics, Chinese PLA General Hospital
  • , Xiaoning GaoAffiliated withDepartment of Pediatrics, Chinese PLA General Hospital
  • , Suoqin TangAffiliated withDepartment of Pediatrics, Chinese PLA General Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Introduction

MYCN amplification is highly associated with malignancy and correlates with poor prognosis in patients with neuroblastoma.

Materials and methods

We developed a novel liposome-MYCN siRNA-folic acid complex, and the transfection efficacy was measured in LA-N-5 cells by cy-3 fluorescence density in each microgram of protein from the transfected cell lysate. MYCN expression and cell growth were studied with quantitative RT-PCR and MTT assays, and the expression of MYCN protein was studied with Western blot, respectively. An SCID mouse model with subcutaneous LA-N-5 xenografted tumor was established. The animals were divided into four groups (n = 5) and they were peritoneally injected with liposome-encapsulated MYCN siRNA (siRNA 125 μg/kg/day), lipid-encapsulated control siRNA, MYCN siRNA, or liposome only, respectively, for 5 consecutive days. The animals were killed 24 h after the last injection, and the expression of MYCN mRNA in tumor tissue was detected by RT-PCR.

Results

Our results are as follows: the transfect efficacy reached 1808.5 ± 140.2 pg siRNA/μg protein in LA-N-5 lysates after treatment with 100 nmol/L MYCN siRNA encapsulated with lipid, and fluorescence could be visualized in 92% of LA-N-5 cells after transfection. At 72 h post-transfection, MYCN mRNA expression in LA-N-5 cells was downregulated by 79.2%, MYCN protein was downregulated by 71.3% and cell growth was inhibited by 66.2%, as measured by MTT assay. In the in vivo study, MYCN mRNA expression was knocked down 53.1% in tumor tissues with injection of liposome-encapsulated MYCN siRNA as compared to control siRNA.

Conclusion

These results suggest that targeted delivery of MYCN siRNA by folate receptor-targeted lipid vesicles into LA-N-5 cells is efficacious and capable of suppressing MYCN mRNA expression both in vitro and in vivo.

Keywords

Neuroblastoma Target therapy MYCN gene Folate receptor Liposome